Cytokinetics CYTK Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's change in AR?
- Cytokinetics (CYTK) reported change in AR of -$10.94M in Q1 2026.
- How has Cytokinetics's change in AR changed year-over-year?
- Cytokinetics's change in AR increased by 25.3% year-over-year, from -$14.64M to -$10.94M.
- What is the long-term trend for Cytokinetics's change in AR?
- Over 3 years (2021 to 2025), Cytokinetics's change in AR has grown at a -71.4% compound annual growth rate (CAGR), from $47.4M to $1.11M.
- What does change in AR mean?
- The net change in money owed to the company by its customers.
- How do you interpret change in AR?
- An increase indicates more cash is tied up in unpaid invoices, potentially signaling slower collections or revenue growth.
- How does change in AR compare across companies?
- Varies by industry; biotech firms often have low receivables unless they have commercialized products.